Lamotrigine (All indications) updated on 04-22-2025

Atrial septal defect

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S19314
R81794		 Kim (Lamotrigine) (Indications NOS), 2026 Atrial septal defect 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 1.28 [0.86;1.92] 35/718   81,249/2,489,078 81,284 718
ref
S10035
R36151		 Blotière (Lamotrigine) (Mixed indications), 2019 Atrial septal defect 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 1.50 [0.80;3.00] 8/2,997   3,268/1,875,733 3,276 2,997
ref
Total 2 studies 1.34 [0.95;1.88] 84,560 3,715
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Kim (Lamotrigine) (Indications NOS), 2026Kim, 2026 1 1.28[0.86; 1.92]81,28471873%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Blotière (Lamotrigine) (Mixed indications), 2019Blotière, 2019 2 1.50[0.80; 3.00]3,2762,99727%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 1.34[0.95; 1.88]84,5603,7150.55.01.0ROB: A: confounding, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Lamotrigine) (Indications NOS; 2: Lamotrigine) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.34[0.95; 1.88]84,5603,7150%NAKim (Lamotrigine) (Indications NOS), 2026 Blotière (Lamotrigine) (Mixed indications), 2019 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.34[0.95; 1.88]84,5603,7150%NAKim (Lamotrigine) (Indications NOS), 2026 Blotière (Lamotrigine) (Mixed indications), 2019 2 Tags Adjustment   - Yes  - Yes 1.34[0.95; 1.88]84,5603,7150%NAKim (Lamotrigine) (Indications NOS), 2026 Blotière (Lamotrigine) (Mixed indications), 2019 2 All studiesAll studies 1.34[0.95; 1.88]84,5603,7150%NAKim (Lamotrigine) (Indications NOS), 2026 Blotière (Lamotrigine) (Mixed indications), 2019 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.34[0.95; 1.88]84,5603,7150%NAKim (Lamotrigine) (Indications NOS), 2026 Blotière (Lamotrigine) (Mixed indications), 2019 20.510.01.0